Comparison of PDE 4 Inhibitors, Rolipram and SB 207499 (ArifloTM, in a Rat Model of Pulmonary Neutrophilia

This publication has 22 references indexed in Scilit:

• The Pathogenesis of Chronic Obstructive Pulmonary Disease
  The American Journal of the Medical Sciences, 1999
• Phosphodiesterase 4B2 Is the Predominant Phosphodiesterase Species and Undergoes Differential Regulation of Gene Expression in Human Monocytes and Neutrophils
  Molecular Pharmacology, 1999
• Lung Cytokines and ARDS
  Chest, 1999
• Regulation of Neutrophil Activation in Acute Lung Injury
  Chest, 1999
• 1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma
  Journal of Medicinal Chemistry, 1998
• Inflammatory Cells in the Bronchial Glands of Smokers with Chronic Bronchitis
  American Journal of Respiratory and Critical Care Medicine, 1997
• Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer
  British Journal of Pharmacology, 1996
• 1 Phosphodiesterase Type IV Inhibitors
  Progress in Medicinal Chemistry, 1996
• Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
  Environmental Health Perspectives, 1994
• The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
  International Journal of Immunopharmacology, 1993